DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Ginkgo Bioworks Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.07−0.20 (-1.95%)
Close on Oct 19, 2026
- Market cap
- $625.29M
- P/E (TTM)
- –
- Dividend yield
- –
Ginkgo Bioworks Holdings, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Cell Engineering | $132.75M | $173.97M | $143.53M | $143.67M | $112.99M | – | – | 78.0% | -23.7% |
| Biosecurity | – | – | $107.92M | $334.04M | $200.85M | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | YoY |
|---|---|---|---|---|---|---|---|---|
| Biosecurity | -$18.93M | -$30.62M | -$3.19M | $71.53M | $9.08M | – | – | -38.2% |
| Cell Engineering | -$95.53M | -$218.57M | -$363.62M | -$249.18M | -$122.05M | – | – | -56.3% |
| Cell Engineering and Biosecurity | -$114.46M | -$249.19M | -$366.82M | -$177.65M | – | – | – | -54.1% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Cell Engineering | $132.75M | $173.97M | $143.53M | $143.67M | $112.99M | – | – | 78.0% | -23.7% |
| Service | $37.41M | $53.07M | $78.98M | $298.59M | $177.81M | $8.73M | – | 22.0% | -29.5% |
| Product | $0 | $0 | $28.95M | $35.46M | $23.04M | $8.71M | – | 0.0% | – |
| Foundry Revenue [Member] | – | – | – | $143.67M | $112.99M | $59.22M | $54.18M | – | – |
By region
From the segment and revenue-disaggregation notes of Ginkgo Bioworks's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.